Hypothalamic CNTF volume transmission shapes cortical noradrenergic excitability upon acute stress

Abstract

Purpose of reviewIn this study, we review the evidence for both long-standing and neweroral antiplatelet agents as secondary prevention in coronary arterydisease, and give our opinion on where each agent's treatment role lies.Recent findingsPlatelets play a pathological role in acute coronary syndromes and aretherefore a major therapeutic target. The caveat to this is that theirphysiological haemostatic role means there must be a careful balancebetween preventing ischaemia and not promoting bleeding. In addition toaccepted oral agents (aspirin and clopidogrel), more potent antiplateletagents have recently become available (prasugrel and ticagrelor) at acost of increased bleeding.SummaryThere is now a choice of three antiplatelet agents to be used inconjunction with aspirin for secondary prevention with dual antiplatelettherapy. Clinicians must now `tailor' the correct therapy for eachpatient, depending on their presentation, clinical features and stage ofrisk.